Further insights into the SAR of α-substituted cyclopropylamine derivatives as inhibitors of histone demethylase KDM1A

European Journal of Medicinal Chemistry

Volumn 92, Issue , 2015, Pages 377-386

  Pieroni, Marco ^a   Annunziato, Giannamaria ^a   Azzali, Elisa ^a   Dessanti, Paola ^b   Mercurio, Ciro ^b   Meroni, Giuseppe ^b   Trifiró, Paolo ^b   Vianello, Paola ^b   Villa, Manuela ^b   Beato, Claudia ^a   Varasi, Mario ^b   Costantino, Gabriele ^a  

^a UNIVERSITY OF PARMA   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Epigenetic; Lysine demethylase; Tranylcypromine

Indexed keywords

1 (ETHOXYCARBONYL) 2 PHENYLCYCLOPROPANECARBOXYLIC ACID; 1 PHENYL 4,7 DIAZASPIRO[2.5]OCTAN 8 ONE; 1 PHENYL 7 OXA 4 AZASPIRO[2.5]OCTAN 5 ONE; 1 [(TERT BUTOXYCARBONYL)AMINO] 2 PHENYLCYCLOPANECARBOXYLATE; 2 BROMO N [1 (HYDROXYMETHYL) 2 PHENYLCYCLOPROPYL]ACETAMIDE; 3 (4 CHLOROPHENYL) 2 PHENYL PROP 2 ENOIC ACID; ANTINEOPLASTIC AGENT; DIETHYL 2 BENZYLIDENEMALONATE; DIETHYL 2 PHENYLCYCLOPROPANE 1,1 DICARBOXYLATE; ETHYL1 [[2 [(TERT BUTOXYCARBONYL)AMINO]ETHYL]AMINO] 2 PHENYLCYCLOPROPANECARBOXYLATE; HISTONE DEMETHYLASE; OXYGENASE INHIBITOR; SELEGILINE; TERT BUTYL [1 (HYDROXYMETHYL) 2 PHENYLCYCLOPROPYL]CARBAMATE; TRANYLCYPROMINE DERIVATIVE; UNCLASSIFIED DRUG; CYCLOPROPANE DERIVATIVE; CYCLOPROPYLAMINE; KDM1A PROTEIN, HUMAN; RECOMBINANT PROTEIN;

ARTICLE; CONTROLLED STUDY; CURTIUS REARRANGEMENT; DNA METHYLATION; ENZYME ACTIVE SITE; ENZYME INHIBITION ASSAY; EPIGENETICS; HISTONE ACETYLATION; HISTONE METHYLATION; HUMAN; TUMOR CELL LINE; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; METABOLISM; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

CYCLOPROPANES; DOSE-RESPONSE RELATIONSHIP, DRUG; HISTONE DEMETHYLASES; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84920853656     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2014.12.032     Document Type: Article

References (50)

1. S.L. Berger, Histone modifications in transcriptional regulation, Curr. Opin. Genet. Dev. 12 (2002) 142-148.
2. T. Jenuwein, C.D. Allis, Translating the histone code, Science 293 (2001) 1074-1080, http://dx.doi.org/10.1126/science.1063127.
3. M.R. Hübner, M.A. Eckersley-Maslin, D.L. Spector, Chromatin organization and transcriptional regulation, Curr. Opin. Genet. Dev. 23 (2013) 89-95, http://dx.doi.org/10.1016/j.gde.2012.11.006.
4. K. Mekhail, D. Moazed, The nuclear envelope in genome organization, expression and stability, Nat. Rev. Mol. Cell. Biol. 11 (2010) 317-328, http://dx.doi.org/10.1038/nrm2894.
5. A.P. Feinberg, B. Vogelstein, Hypomethylation distinguishes genes of some human cancers from their normal counterparts, Nature 301 (1983) 89-92, http://dx.doi.org/10.1038/301089a0.
6. V.M. Richon, Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor, Br. J. Cancer 95 (2006) S2-S6, http://dx.doi.org/10.1038/sj.bjc.6603463.
7. H. Nakajima, Y.B. Kim, H. Terano, M. Yoshida, S. Horinouchi, FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor, Exp. Cell. Res. 241 (1998) 126-133, http://dx.doi.org/10.1006/excr.1998.4027.
8. M. Haberland, R.L. Montgomery, E.N. Olson, The many roles of histone deacetylases in development and physiology: implications for disease and therapy, Nat. Rev. Genet. 10 (2009) 32-42, http://dx.doi.org/10.1038/nrg2485.
9. A.J.M. de Ruijter, A.H. van Gennip, H.N. Caron, S. Kemp, A.B.P. van Kuilenburg, Histone deacetylases (HDACs): characterization of the classical HDAC family, Biochem. J. 370 (2003) 737-749, http://dx.doi.org/10.1042/BJ20021321.
10. P. Filippakopoulos, S. Knapp, Targeting bromodomains: epigenetic readers of lysine acetylation, Nat. Rev. Drug Discov. 13 (2014) 337-356, http://dx.doi.org/10.1038/nrd4286.
11. R.M. Labbe, A. Holowatyj, Z.-Q. Yang, Histone lysine demethylase (KDM) subfamily 4: structures, functions and therapeutic potential, Am. J. Transl. Res. 6 (2013) 1-15.
12. C. Martin, Y. Zhang, The diverse functions of histone lysine methylation, Nat. Rev. Mol. Cell. Biol. 6 (2005) 838-849, http://dx.doi.org/10.1038/nrm1761.
13. D. Rotili, A. Mai, Targeting histone demethylases a new avenue for the fight against cancer, Genes. Cancer 2 (2011) 663-679, http://dx.doi.org/10.1177/1947601911417976.
14. N. Mosammaparast, Y. Shi, Reversal of histone methylation: biochemical and molecular mechanisms of histone demethylases, Annu. Rev. Biochem. 79 (2010) 155-179, http://dx.doi.org/10.1146/annurev.biochem.78.070907.103946.
15. A. Karytinos, F. Forneris, A. Profumo, G. Ciossani, E. Battaglioli, C. Binda, et al., A novel Mammalian flavin-dependent histone demethylase, J. Biol. Chem. 284 (2009) 17775-17782, http://dx.doi.org/10.1074/jbc.M109.003087.
16. C. Loenarz, C.J. Schofield, Expanding chemical biology of 2-oxoglutarate oxygenases, Nat. Chem. Biol. 4 (2008) 152-156, http://dx.doi.org/10.1038/nchembio0308-152.
17. F. Forneris, C. Binda, E. Battaglioli, A. Mattevi, LSD1: oxidative chemistry for multifaceted functions in chromatin regulation, Trends Biochem. Sci. 33 (2008) 181-189, http://dx.doi.org/10.1016/j.tibs.2008.01.003.
18. Y. Shi, F. Lan, C. Matson, P. Mulligan, J.R. Whetstine, P.A. Cole, et al., Histone demethylation mediated by the nuclear amine oxidase homolog LSD1, Cell 119 (2004) 941-953, http://dx.doi.org/10.1016/j.cell.2004.12.012.
19. D.N. Ciccone, H. Su, S. Hevi, F. Gay, H. Lei, J. Bajko, et al., KDM1B is a histone H3K4 demethylase required to establish maternal genomic imprints, Nature 461 (2009) 415-418, http://dx.doi.org/10.1038/nature08315.
20. T. Schenk, W.C. Chen, S. Göllner, L. Howell, L. Jin, K. Hebestreit, et al., Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia, Nat. Med. 18 (2012) 605-611, http://dx.doi.org/10.1038/nm.2661.
21. J.H. Schulte, S. Lim, A. Schramm, N. Friedrichs, J. Koster, R. Versteeg, et al., Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy, Cancer Res. 69 (2009) 2065-2071, http://dx.doi.org/10.1158/0008-5472.CAN-08-1735.
22. F. Crea, L. Sun, A. Mai, Y.T. Chiang, W.L. Farrar, R. Danesi, et al., The emerging role of histone lysine demethylases in prostate cancer, Mol. Cancer 11 (2012) 52, http://dx.doi.org/10.1186/1476-4598-11-52.
23. T. Suzuki, N. Miyata, Lysine demethylases inhibitors, J. Med. Chem. 54 (2011) 8236-8250, http://dx.doi.org/10.1021/jm201048w.
24. P. Vianello, O.A. Botrugno, A. Cappa, G. Ciossani, P. Dessanti, A. Mai, et al., Synthesis, biological activity and mechanistic insights of 1-substituted cyclopropylamine derivatives: a novel class of irreversible inhibitors of histone demethylase KDM1A, Eur. J. Med. Chem. 86 (2014) 352-363, http://dx.doi.org/10.1016/j.ejmech.2014.08.068.
25. D.M.Z. Schmidt, D.G. McCafferty, trans-2-Phenylcyclopropylamine is a mechanism-based inactivator of the histone demethylase LSD1, Biochem. Mosc. 46 (2007) 4408-4416, http://dx.doi.org/10.1021/bi0618621.
26. M.G. Lee, C. Wynder, D.M. Schmidt, D.G. McCafferty, R. Shiekhattar, Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications, Chem. Biol. 13 (2006) 563-567, http://dx.doi.org/10.1016/j.chembiol.2006.05.004.
27. M. Yang, J.C. Culhane, L.M. Szewczuk, P. Jalili, H.L. Ball, M. Machius, et al., Structural basis for the inhibition of the LSD1 histone demethylase by the antidepressant trans-2-phenylcyclopropylamine, Biochem. Mosc. 46 (2007) 8058-8065, http://dx.doi.org/10.1021/bi700664y.
28. J.C. Culhane, D. Wang, P.M. Yen, P.A. Cole, Comparative analysis of small molecules and histone substrate analogues as LSD1 lysine demethylase inhibitors, J. Am. Chem. Soc. 132 (2010) 3164-3176, http://dx.doi.org/10.1021/ja909996p.
29. E. Metzger, M. Wissmann, N. Yin, J.M. Müller, R. Schneider, A.H.F.M. Peters, et al., LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription, Nature 437 (2005) 436-439, http://dx.doi.org/10.1038/nature04020.
30. Y. Huang, E. Greene, T.M. Stewart, A.C. Goodwin, S.B. Baylin, P.M. Woster, et al., Inhibition of lysine-specific demethylase 1 by polyamine analogues results in reexpression of aberrantly silenced genes, Proc. Natl. Acad. Sci. 104 (2007) 8023-8028, http://dx.doi.org/10.1073/pnas.0700720104.
31. S.K. Sharma, Y. Wu, N. Steinbergs, M.L. Crowley, A.S. Hanson, R.A. Casero, et al., (Bis)urea and (Bis)thiourea inhibitors of lysine-specific demethylase 1 as epigenetic modulators, J. Med. Chem. 53 (2010) 5197-5212, http://dx.doi.org/10.1021/jm100217a.
32. J. Wang, F. Lu, Q. Ren, H. Sun, Z. Xu, R. Lan, et al., Novel histone demethylase LSD1 inhibitors selectively target cancer cells with pluripotent stem cell properties, Cancer Res. 71 (2011) 7238-7249, http://dx.doi.org/10.1158/0008-5472.CAN-11-0896.
33. V. Sorna, E.R. Theisen, B. Stephens, S.L. Warner, D.J. Bearss, H. Vankayalapati, et al., High-throughput virtual screening identifies novel N′-(1-phenylethylidene)-benzohydrazides as potent, specific, and reversible LSD1 inhibitors, J. Med. Chem. 56 (2013) 9496-9508, http://dx.doi.org/10.1021/jm400870h.
34. N. Johnson, J. Kasparec, W. Miller, M. Rouse, D. Suarez, X. Tian, 2012, Cyclopropylamines as Lsd1 Inhibitors, WO/2012/135113, http://patentscope.wipo.int/search/en/detail.jsf?docId=WO2012135113&recNum=66&docAn= US2012030552&queryString=EN-ALL:nmr%20AND%20PA:glaxosmithkline&maxRec=557 (accessed 26.09.14).
35. A. Ortega Muñoz, M.C.T. Fyfe, M. Martinell Pedemonte, M. de los Á. Estiarte Martínez, N. Valls Vidal, G. Kurz, et al., 2012, (Hetero)aryl Cyclopropylamine Compounds as Lsd1 Inhibitors, WO/2013/057320, http://patentscope.wipo.int/search/en/detail.jsf?docId=WO2013057320 &recNum=2&docAn=EP2012070898 &queryString=&maxRec=17259 (accessed 26.09.14).
36. A. Ortega Muñoz, M.C.T. Fyfe, M. Martinell Pedemonte, M. de los Á. Estiarte Martínez, N. Valls Vidal, G. Kurz, et al., 2013, (Hetero)aryl Cyclopropylamine Compounds as Lsd1 Inhibitors, WO/2013/057322, http://patentscope.wipo.int/search/en/WO2013057322 (accessed 26.09.14).
37. D.M.Z. Schmidt, D.G. McCafferty, trans-2-Phenylcyclopropylamine is a mechanism-based Inactivator of the histone demethylase LSD1, Biochem. Mosc. 46 (2007) 4408-4416, http://dx.doi.org/10.1021/bi0618621.
38. C.D. Bray, F. Minicone, Stereocontrolled synthesis of quaternary cyclopropyl esters, Chem. Commun. 46 (2010) 5867-5869, http://dx.doi.org/10.1039/C0CC01333A.
39. M. Shiozaki, K. Maeda, T. Miura, Y. Ogoshi, J. Haas, A.M. Fryer, et al., Novel N-substituted 2-phenyl-1-sulfonylamino-cyclopropane carboxylates as selective ADAMTS-5 (aggrecanase-2) inhibitors, Bioorg. Med. Chem. Lett. 19 (2009) 1575-1580, http://dx.doi.org/10.1016/j.bmcl.2009.02.024.
40. N. Guibourt, M.A. Ortega, L.J. Castro-Palomino, 2010, Patent Appl. WO 2010043721.
41. N. Guibourt, M.A. Ortega, L.J. Castro-Palomino, 2010, Patent Appl. WO 2010084160.
42. M.A. Ortega, L.J. Castro-Palomino, M.C.T. Fyfe, 2011, Patent Appl. WO 2011035941.
43. S. Mimasu, T. Sengoku, S. Fukuzawa, T. Umehara, S. Yokoyama, Crystal structure of histone demethylase LSD1 and tranylcypromine at 2.25 A, Biochem. Biophys. Res. Commun. 366 (2008) 15-22, http://dx.doi.org/10.1016/j.bbrc.2007.11.066.
44. F.C. Bernstein, T.F. Koetzle, G.J. Williams, E.F. Meyer, M.D. Brice, J.R. Rodgers, et al., The Protein Data Bank: a computer-based archival file for macromolecular structures, J. Mol. Biol. 112 (1977) 535-542.
45. Prime, version 3.0, Schrödinger, LLC, New York, NY, 2011.
46. Protein Preparation Wizard, Schrödinger, LLC, New York, NY, 2011.
47. LigPrep, version 2.8, Schrödinger, LLC, New York, NY, 2013.
48. Jaguar, version 8.2, Schrödinger, LLC, New York, NY, 2013.
49. P. Geerlings, F. De Proft, W. Langenaeker, Conceptual density functional theory, Chem. Rev. 103 (2003) 1793-1874, http://dx.doi.org/10.1021/cr990029p.
50. B. Marten, K. Kim, C. Cortis, R.A. Friesner, R.B. Murphy, M.N. Ringnalda, et al., New model for calculation of solvation free energies: correction of selfconsistent reaction field continuum dielectric theory for short-range hydrogen-bonding effects, J. Phys. Chem. 100 (1996) 11775-11788, http://dx.doi.org/10.1021/jp953087x. dx.doi.org/10.1021/jp953087x.